证券代码：605016 证券简称：百龙创园 公告编号：2023-038 山东百龙创园生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 09 月 08 日(星期五) 上午 09:00-10:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 01 日(星期五) 至 09 月 07 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 blcyzqb@sdblcy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 山东百龙创园生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 ...

一、募集资金基本情况 （一）募集资金到位情况 公司 2019 年第三次临时股东大会决议，本公司申请增加注册资本人民币不超过 31,800,000.00 元，经中国证券监督管理委员会证监许可[2021]1010 号文核准，同意本公司向社 会公众发行人民币普通股（A股）不超过 31,800,000.00股。本公司实际向社会公众发行人民币 普通股（A 股）31,800,000.00 股，发行价为 14.62 元/每股，募集资金总额为人民币 464,916,000.00 元，扣除与发行有关的费用人民币 58,698,839.94 元，实际可使用募集资金净额 为人民币 406,217,160.06 元。 上述资金已于 2021 年 4 月 15 日全部到位，业经致同会计师事务所（特殊普通合伙）于 2021 年 4 月 15 日出具了致同验字（2021）第 110C000179 号《验资报告》。 本公司对募集资金采取了专户存储制度，并与保荐机构中德证券有限责任公司和存放募 集资金的商业银行签订《募集资金专户存储三方监管协议》，用于存放上述募集资金，以保 证募集资金使用安全。 （二）募集资金使用情况 截至 2023 年 6 ...

证券代码：605016 证券简称：百龙创园 公告编号：2023-035 山东百龙创园生物科技股份有限公司 关于 2023 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之 《第十四号——食品制造》相关规定，现将山东百龙创园生物科技股份有限公司 （简称"公司"）2023 年半年度主要经营数据（未经审计）公告如下： 一、报告期主要经营数据 单位：万元 1 2023 年 1-6 月，实现营业收入 41,275.68 万元，同比增长 5.15%。实现主营 业务收入为 40,671.90 万元，同比增长 7.70%。实现归属于上市公司股东净利润 9,109.96 万元，同比增长 16.12%。主营业务收入构成情况具体如下： | 项目 | 2023 年 1-6 | 月 | 2022 年 1-6 | 月 | | --- | --- | --- | --- | --- | | | 金额（万元） | 比例（%） | 金额（万元） | 比例（% ...

证券代码：605016 证券简称：百龙创园 公告编号：2023-037 （2）公司 2023 年半年度报告及摘要的内容和格式符合中国证监会和上海证 券交易所的规定。所包含的信息真实、准确、完整地反映了公司当期的主要经营 情况和财务状况，不存在虚假记载、误导性陈述和重大遗漏； 山东百龙创园生物科技股份有限公司 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）第三届监事会第五 次会议于 2023 年 8 月 24 日上午 10：00 在公司办公楼一楼第二会议室召开，本 次会议的会议通知和材料已于 2023 年 8 月 14 日通过邮件等方式发出。会议由监 事会主席干昭波先生主持，应到监事 5 人，实到监事 5 人。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，表决形成的决议合法、有效。 二、监事会会议审议情况 1、审议通过《关于 2023 年半年度报告及其摘要的议案》 经审议 ...

山东百龙创园生物科技股份有限公司 第三届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 证券代码：605016 证券简称：百龙创园 公告编号：2023-036 1、审议通过《关于 2023 年半年度报告及其摘要的议案》 具体内容详见公司同日在上海证券交易所官方网站及指定媒体上披露的 《2023 年半年度报告及其摘要》。 审议结果：表决票 9 票，赞成票 9 票，反对票 0 票，弃权票 0 票。 2、审议通过《关于 2023 年半年度募集资金存放与使用情况专项报告的议案》 具体内容详见公司同日在上海证券交易所官方网站及指定媒体上披露的 《2023 年半年度募集资金存放与使用情况专项报告》。 审议结果：表决票 9 票，赞成票 9 票，反对票 0 票，弃权票 0 票。 独立董事对本议案发表了同意的独立意见。 特此公告。 山东百龙创园生物科技股份有限公司董事会 山东百龙创园生物科技股份有限公司（以下简称"公司"）第三届董事会第五 次会议于 2023 年 8 月 24 日上午 9： ...

证券代码：605016 证券简称：百龙创园 公告编号：029 山东百龙创园生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 06 月 05 日(星期一)下午 15:00-16:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 29 日(星期一)至 06 月 02 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 blcyzqb@sdblcy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 山东百龙创园生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资 ...

Financial Performance - The company achieved total operating revenue of 721,893,633.69 RMB, representing a year-on-year growth of 10.49%[22]. - Net profit attributable to shareholders reached 150,801,475.89 RMB, an increase of 44.34% compared to the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 141,042,480.95 RMB, up 47.96% year-on-year[22]. - The net cash flow from operating activities was 149,815,201.01 RMB, reflecting a significant increase of 55.74% due to higher receivables recovery[22]. - By the end of 2022, the net assets attributable to shareholders amounted to 1,344,960,315.03 RMB, a growth of 11.76% from the previous year[22]. - Total assets increased to 1,471,953,421.03 RMB, marking a year-on-year growth of 14.77%[22]. - Basic earnings per share were 0.85 RMB, a decrease of 5.56% compared to 0.90 RMB in 2021[21]. - The weighted average return on equity rose to 11.84%, an increase of 1.54 percentage points from the previous year[21]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 3,017.84 million (including tax), which equates to RMB 1.7 per 10 shares based on a total share capital of 177,520,000 shares as of December 31, 2022[5]. - The company intends to increase its total share capital to 248,528,000 shares by converting 4 shares for every 10 shares held from capital reserves[5]. - The proposed cash dividend is RMB 1.7 per 10 shares, totaling RMB 30.18 million, which accounts for 20.01% of the net profit for the year[162]. Audit and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of the financial report[4]. - There are no instances of non-operational fund occupation by controlling shareholders or related parties reported[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with shareholders through various platforms[127]. - The company’s governance structure complies with relevant laws and regulations, with ongoing improvements planned to enhance operational standards[128]. Business Operations and Market Position - The company operates in the biotechnology sector, focusing on functional sugars and dietary fibers[12]. - The company is headquartered in the National High-tech Industrial Development Zone in Dezhou, Shandong Province[16]. - The company’s stock is listed on the Shanghai Stock Exchange under the code 605016[18]. - The company operates in the "C14 Food Manufacturing" sector, focusing on the R&D, production, and sales of prebiotics, dietary fibers, and health sweeteners, with significant revenue contributions from these product lines[46]. - The company has established a comprehensive sales network covering major markets in China and globally, with dedicated personnel in key cities[77]. Product Development and Innovation - The company launched new high-end prebiotic products and health sweeteners, achieving significant sales growth, with health sweeteners' production increasing by 27.77% and sales by 28.16%[37]. - The company obtained 14 authorized invention patents in 2022, including 12 domestic and 2 foreign patents, enhancing its innovation capabilities[40]. - The company has established a flexible production model that allows for rapid adjustments to product types and specifications based on market demand[60]. - The company is investing in new product development, focusing on innovative technologies to enhance user experience and market competitiveness[137]. Market Trends and Future Outlook - The prebiotic industry in China is projected to reach a total output value of 3.624 billion yuan by 2025, while the global market is expected to reach 18.047 billion yuan[48]. - The dietary fiber market in China is anticipated to reach 5.527 billion yuan by 2026, with the global market expected to reach 22.913 billion yuan[49]. - The company plans to continue expanding its market presence and product offerings in response to growing domestic and international demand[81]. - The company aims to enhance its core competitiveness by leveraging technological research and development, aligning with the "Healthy China 2030" initiative for sustainable growth[117]. Environmental and Social Responsibility - The company has implemented a comprehensive self-monitoring plan for pollutant emissions as per regulations[175]. - The company has been included in the first batch of Shandong Province's green factories and the national green factory list[178]. - The company actively engages in charitable activities, donating 320,000 RMB for the purchase of a negative pressure ambulance[183]. - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 25% over the next five years[138]. Risk Management - The company has outlined potential risks in its future development plans, which investors should be aware of[8]. - The company faces risks from market competition and potential product substitution, emphasizing the need for continuous R&D investment to maintain technological advantages[121]. - Fluctuations in raw material prices, such as starch and sugar, could significantly impact product costs and profit margins, necessitating careful management[122]. - The company is exposed to exchange rate risks due to its reliance on USD for export settlements, which may affect financial performance[123].

Financial Performance - The company's operating revenue for Q1 2023 was ¥194,476,395.76, representing a decrease of 1.70% compared to the same period last year[3] - Net profit attributable to shareholders of the listed company was ¥44,446,732.71, an increase of 9.13% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥40,739,493.69, up by 9.54% compared to the previous year[3] - The net profit for Q1 2023 was CNY 44,446,732.71, an increase of 9.1% compared to CNY 40,729,310.25 in Q1 2022[14] - Operating profit for Q1 2023 reached CNY 53,794,236.75, up from CNY 48,231,635.35 in the same period last year, reflecting a growth of 3.3%[14] - The total comprehensive income for Q1 2023 was CNY 44,446,732.71, compared to CNY 40,729,310.25 in Q1 2022, an increase of 9.1%[14] Cash Flow - The net cash flow from operating activities was ¥22,526,488.01, showing a significant increase of 324.62% year-on-year[3] - The net cash flow from operating activities was CNY 22,526,488.01, significantly higher than CNY 5,305,087.33 in Q1 2022, marking an increase of 325.5%[16] - Cash inflow from operating activities totaled CNY 183,067,625.06, compared to CNY 174,064,180.85 in Q1 2022, indicating a growth of 5.7%[16] - Cash outflow from operating activities decreased to CNY 160,541,137.05 from CNY 168,759,093.52 in the previous year, a reduction of 4.5%[16] - The company reported a net cash flow from investing activities of CNY 41,756,809.23, a turnaround from a negative cash flow of CNY -4,556,993.51 in Q1 2022[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,546,683,431.22, reflecting a growth of 5.08% from the end of the previous year[4] - Total assets as of March 31, 2023, amounted to CNY 1,546,683,431.22, compared to CNY 1,471,953,421.03 at the end of 2022, showing an increase of 5.08%[11] - The company's total liabilities increased to CNY 157,276,383.48 in Q1 2023 from CNY 126,993,106.00 in the previous year, indicating a rise of 23.7%[11] - The total equity of the company as of March 31, 2023, was CNY 1,389,407,047.74, an increase from CNY 1,344,960,315.03 at the end of 2022, reflecting a growth of 3.3%[11] Shareholder Information - Basic earnings per share decreased by 21.88% to ¥0.25 due to an increase in total share capital[5] - Basic and diluted earnings per share for Q1 2023 were CNY 0.25, down from CNY 0.32 in Q1 2022, reflecting a decrease of 21.9%[14] - The total number of ordinary shareholders at the end of the reporting period was 6,899[6] Research and Development - Research and development expenses rose to CNY 8,629,535.00 in Q1 2023, up from CNY 5,254,208.04 in Q1 2022, reflecting a 64.5% increase[13] Non-Recurring Gains - The company reported non-recurring gains of ¥3,858,583.08 from government subsidies closely related to its normal business operations[4] - The company reported a significant increase in other income to CNY 3,858,583.08 in Q1 2023, compared to CNY 1,578,330.29 in Q1 2022, marking a growth of 144.4%[13] Future Outlook - The company has not provided specific guidance for future performance in the conference call, indicating a cautious outlook amid rising costs and fluctuating revenues[13]

证券代码：605016 证券简称：百龙创园 公告编号：2022-043 山东百龙创园生物科技股份有限公司 关于参加山东辖区上市公司 2022 年度投资者网上集 体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为加强与投资者之间的互动交流，构建和谐稳定的投资者关系，山东百龙创 园生物科技股份有限公司（以下简称"公司"）拟定于 2022 年 11 月 16 日参加由 山东证监局、山东上市公司协会联合举办并由深圳市全景网络有限公司承办的 "山东辖区上市公司 2022 年度投资者网上集体接待日"活动，现将有关事项公 告如下： 一、活动时间 2021 年 11 月 16 日（星期三）14:00-16:00 二、活动方式 本次集体接待日活动将采取全景路演平台线上交流的方式举行，投资者可以 登录全景网"投资者关系互动平台"（http://ir.p5w.net/）参与本次活动。 三、参加人员 届时，公司董事、总经理禚洪建先生，财务总监李莉女士，董事会秘书谷俊 超先生将参与本次投资者网上集体接待日活动，与投资者进行在线 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥157,808,193.25, a decrease of 4.77% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 reached ¥39,537,058.72, an increase of 69.98% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥33,842,428.86, up 46.94% from the previous year[5] - Basic earnings per share for Q3 2022 was ¥0.22, reflecting a 22.22% increase year-on-year[5] - The company's revenue for the first three quarters of 2022 reached ¥550,364,964.66, an increase of 16.54% compared to ¥472,181,819.50 in the same period of 2021[27] - The net profit for the first three quarters of 2022 was ¥117,990,687.04, representing a growth of 57.56% from ¥75,041,512.48 in the previous year[27] - The total comprehensive income for the period was ¥117,990,687.04, compared to ¥75,041,512.48 in the previous year, indicating strong overall performance[29] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥107,197,630.33, an increase of 71.21% compared to the same period last year[5] - Cash flow from operating activities generated a net amount of ¥107,197,630.33, compared to ¥62,612,664.46 in the same period last year, showing a significant improvement[29] - The company's cash inflow from operating activities totaled ¥598,015,458.69, an increase from ¥466,874,130.28 in the same period last year[29] - The net cash flow from investing activities was -170,324,042.69, compared to -331,623,040.07 in the previous period, indicating an improvement[31] - The total cash inflow from financing activities was 212,704.16, significantly lower than 434,832,000.00 in the previous period[31] - The net cash flow from financing activities was -10,291,051.68, contrasting with a positive flow of 352,250,108.94 in the previous period[31] - The total cash and cash equivalents at the end of the period amounted to 217,635,303.25, slightly up from 213,432,123.62 in the previous period[31] - The cash and cash equivalents decreased by 73,406,121.44 during the period, compared to an increase of 83,239,733.33 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,402,938,157.76, representing a 9.39% increase from the end of the previous year[7] - Current assets totaled CNY 822,450,420.70, slightly down from CNY 831,888,807.18 in the previous year, indicating a decrease of about 1.8%[21] - Cash and cash equivalents were reported at CNY 239,645,126.65, down from CNY 305,241,527.66, representing a decline of approximately 21.5%[18] - Accounts receivable increased to CNY 148,539,115.62 from CNY 141,997,582.84, showing a growth of about 4.0%[21] - Inventory levels rose to CNY 153,188,624.01, compared to CNY 121,820,451.63, marking an increase of approximately 25.6%[21] - Non-current assets totaled CNY 580,487,737.06, up from CNY 450,622,579.31, reflecting an increase of around 29.0%[21] - The total liabilities rose to ¥89,782,590.83, compared to ¥79,050,080.82 in the previous year, reflecting a 13.86% increase[27] - The total liabilities included accounts payable of CNY 31,376,803.22, slightly down from CNY 32,324,326.80, indicating a decrease of about 2.9%[21] Shareholder Information - Shareholders' equity attributable to the parent company was ¥1,313,155,566.93, up 9.11% from the end of the previous year[7] - The total equity increased to ¥1,313,155,566.93, up from ¥1,203,461,305.67, marking an increase of 9.13%[27] - The top ten shareholders hold a total of 47.34% of the shares, with Dou Baode being the largest shareholder[14] - The company has a pledge situation with 9,100,000 shares pledged by major shareholder Dou Baode[14] Research and Development - Research and development expenses increased to ¥20,248,204.34 in 2022, up 66.73% from ¥12,121,443.66 in 2021, indicating a focus on innovation[27] Non-Recurring Gains - The company reported non-recurring gains of ¥5,694,629.86 for the reporting period[11] - The increase in net profit was attributed to growth in domestic and international customer demand and optimization of product structure[11]